Premium
“Chemical” surgery in treating basal cell carcinoma in elderly
Author(s) -
Chiriac Anca E.,
Balan Gheorghe G.,
Pinteala Tudor,
Chiriac Anca,
Betiu Mircea
Publication year - 2018
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12753
Subject(s) - vismodegib , medicine , basal cell carcinoma , imiquimod , dermatology , cryosurgery , curettage , incidence (geometry) , radiation therapy , surgery , basal cell , population , physics , environmental health , optics
The incidence of basal cell carcinoma (BCC) has been increasing in the last decades due to population aging and precise diagnosis. The difficulty that physicians face frequently is related to the treatment decision for BCC; when treating BCC, correct and personalized choices must be taken into consideration by selecting from a large variety of therapeutic options such as: surgical excision (“the golden standard therapy”), electrodessication, cryosurgery, radiation therapy, laser, photodynamic therapy, curettage, topical treatment (imiquimod, 5‐fluorouracil, vismodegib), or combining different treatments. The present authors present series of cases of patients diagnosed with BCC, highlighting that “chemical surgery” using 70% trichloroacetic acid could be a valuable option in the treatment of nonaggressive BCC of the face.